open access

Ahead of print
Research Letter
Submitted: 2021-07-31
Accepted: 2021-10-24
Early publication date: 2021-11-15
Get Citation

Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization

Jaroslaw Meyer-Szary1, Magdalena Bazgier1, Paulina Lubocka1, Karolina Dorniak2, Robert Sabiniewicz1
DOI: 10.5603/CJ.a2021.0152
·
Pubmed: 34787887
Affiliations
  1. Deptartment of Pediatric Cardiology and Congenital Heart Diseases, Medical University of Gdańsk, M. Skłodowskiej-Curie 3a, 80-210 Gdańsk, Poland
  2. Department of Noninvasive Cardiac Diagnostics, Medical University of Gdansk, Skłodowskiej-Curie 3a, 80-210 Gdansk, Poland

open access

Ahead of print
Research letters — COVID-19
Submitted: 2021-07-31
Accepted: 2021-10-24
Early publication date: 2021-11-15

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Cardiac magnetic resonance characteristics of acute myocarditis occurring after mRNA-based COVID-19 vaccines immunization

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Research Letter

Early publication date

2021-11-15

DOI

10.5603/CJ.a2021.0152

Pubmed

34787887

Authors

Jaroslaw Meyer-Szary
Magdalena Bazgier
Paulina Lubocka
Karolina Dorniak
Robert Sabiniewicz

References (10)
  1. Habib MB, Hamamyh T, Elyas A, et al. Acute myocarditis following administration of BNT162b2 vaccine. IDCases. 2021; 25: e01197.
  2. Deb A, Abdelmalek J, Iwuji K, et al. Acute myocardial injury following COVID-19 vaccination: a case report and review of current evidence from vaccine adverse events reporting system database. J Prim Care Community Health. 2021; 12: 21501327211029230.
  3. Watkins K, Griffin G, Septaric K, et al. Myocarditis after BNT162b2 vaccination in a healthy male. Am J Emerg Med. 2021 [Epub ahead of print].
  4. Baden LR, El Sahly HM, Essink B, et al. COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384(5): 403–416.
  5. Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603–2615.
  6. Maron B, Udelson J, Bonow R, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. Circulation. 2015; 132(22).
  7. Muthukumar A, Narasimhan M, Li QZ, et al. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine. Circulation. 2021; 144(6): 487–498.
  8. Shay DK, Shimabukuro TT, DeStefano F. Myocarditis occurring after immunization with mRNA-Based COVID-19 vaccines. JAMA Cardiol. 2021; 6(10): 1115–1117.
  9. Bajaj R, Sinclair H, Patel K, et al. Delayed-onset myocarditis following COVID-19. Lancet Resp Med. 2021; 9(4): e32–e34.
  10. Pfizer-BioNTech. Vaccines and Related Biological Products Advisory Committee Meeting FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine Sponsor: Pfizer and BioNTech. N Engl J Med. 2020.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl